Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-HSCT with α/β T-cell Depletion and Reduced Intensity Conditioning for Hematologic Malignancies and Aplastic Anemia
NCT03531736Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2018
- Primary completion
- May 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of antithymocyte globulin, fludarabine, cyclophosphamide and rituximab in hematologic malignancy and aplastic anemia, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Rate of donor Neutrophil Engraftment at 30 days. Started May 2018; status: active, not recruiting.
02
Drugs
antithymocyte globulinfludarabinecyclophosphamiderituximab
03
Conditions
hematologic malignancyaplastic anemia
Beyond the preview
Go deeper on NCT03531736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531736.